CARY, N.C., FEBRUARY 18, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by SpringWorks Therapeutics as a limited distribution specialty pharmacy provider for GOMEKLITM (mirdametinib), which is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
GOMEKLI, which was approved by the U.S. Food and Drug Administration (FDA) on February 11, 2025, based on response data from the ReNeu trial, is an oral MEK inhibitor for the treatment of adult and pediatric patients 2 years of age and older with NF1-PN. NF1 is a rare genetic disorder that arises from mutations in the NF1 gene. As a multisystem disease that starts as early as infancy and can span the entire lifetime of affected individuals, patients with NF1 have a 30% to 50% lifetime risk of developing plexiform neurofibromas (PN). GOMEKLI is the first and only treatment approved by the FDA for both adult and pediatric patients with NF1-PN.
“Biologics is privileged to partner in the distribution of GOMEKLI,” said George Paschal, sr. director, business development. “We are excited to collaborate with SpringWorks Therapeutics to help make this therapy available to patients with NF1-PN.”
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For more information about this drug and the treatment of NF1-PN, please click https://www.gomekli.com
For more information about GOMEKLI, including full prescribing information, please click Prescribing Information
GOMEKLITM is a trademark of SpringWorks Therapeutics, Inc.